This company has been marked as potentially delisted and may not be actively trading. Interpace Biosciences (IDXG) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock IDXG vs. LH, DGX, DVA, CHE, CRVL, AMED, MD, AMN, CCRN, and BTCYShould you be buying Interpace Biosciences stock or one of its competitors? The main competitors of Interpace Biosciences include Labcorp (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), CorVel (CRVL), Amedisys (AMED), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), and Biotricity (BTCY). Interpace Biosciences vs. Its Competitors Labcorp Quest Diagnostics DaVita Chemed CorVel Amedisys Pediatrix Medical Group AMN Healthcare Services Cross Country Healthcare Biotricity Interpace Biosciences (NASDAQ:IDXG) and Labcorp (NYSE:LH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Do insiders & institutionals have more ownership in IDXG or LH? 5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is IDXG or LH more profitable? Interpace Biosciences has a net margin of 10.39% compared to Labcorp's net margin of 5.66%. Labcorp's return on equity of 15.45% beat Interpace Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Interpace Biosciences10.39% -8.09% 37.14% Labcorp 5.66%15.45%7.02% Do analysts prefer IDXG or LH? Labcorp has a consensus target price of $289.58, indicating a potential upside of 4.18%. Given Labcorp's stronger consensus rating and higher probable upside, analysts clearly believe Labcorp is more favorable than Interpace Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Interpace Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Labcorp 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.62 Which has more risk & volatility, IDXG or LH? Interpace Biosciences has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Labcorp has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Which has stronger valuation and earnings, IDXG or LH? Labcorp has higher revenue and earnings than Interpace Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterpace Biosciences$40.21M0.10$800KN/AN/ALabcorp$13.01B1.78$746M$9.0630.68 Does the media refer more to IDXG or LH? In the previous week, Labcorp had 25 more articles in the media than Interpace Biosciences. MarketBeat recorded 25 mentions for Labcorp and 0 mentions for Interpace Biosciences. Labcorp's average media sentiment score of 1.33 beat Interpace Biosciences' score of 0.00 indicating that Labcorp is being referred to more favorably in the news media. Company Overall Sentiment Interpace Biosciences Neutral Labcorp Positive SummaryLabcorp beats Interpace Biosciences on 11 of the 14 factors compared between the two stocks. Get Interpace Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDXG vs. The Competition Export to ExcelMetricInterpace BiosciencesSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.88M$83.93M$5.75B$9.62BDividend YieldN/AN/A4.40%4.10%P/E RatioN/A11.0031.3026.05Price / Sales0.10107.86432.98193.75Price / Cash1.9918.4137.7358.48Price / Book-0.067.139.536.61Net Income$800K-$26.48M$3.26B$265.65M Interpace Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDXGInterpace BiosciencesN/A$0.88flatN/A-39.3%$3.88M$40.21M0.00152LHLabcorp4.7797 of 5 stars$269.16+0.6%$289.58+7.6%+20.6%$22.24B$13.01B29.7170,000Positive NewsDGXQuest Diagnostics4.5294 of 5 stars$178.62+0.1%$186.00+4.1%+17.8%$19.94B$9.87B21.3956,000News CoveragePositive NewsInsider TradeDVADaVita4.4933 of 5 stars$132.08+2.3%$164.00+24.2%-7.9%$9.23B$12.82B12.9976,000Positive NewsAnalyst UpgradeCHEChemed4.9904 of 5 stars$442.41+2.4%$579.75+31.0%-19.5%$6.30B$2.43B22.7515,695Positive NewsCRVLCorVel2.0176 of 5 stars$89.81+2.7%N/A-9.7%$4.49B$895.59M46.295,075News CoveragePositive NewsInsider TradeAMEDAmedisys3.1483 of 5 stars$100.950.0%$100.50-0.4%+3.6%$3.32B$2.35B39.2819,000Positive NewsShort Interest ↑MDPediatrix Medical Group2.0677 of 5 stars$14.71+4.1%$16.67+13.3%+54.0%$1.23B$2.01B11.404,305News CoveragePositive NewsAnalyst RevisionAMNAMN Healthcare Services4.4348 of 5 stars$17.74+7.6%$28.25+59.3%-59.2%$631.97M$2.98B-2.282,968News CoverageCCRNCross Country Healthcare3.3252 of 5 stars$12.76+0.7%$17.93+40.5%-2.3%$415.10M$1.34B-49.088,205BTCYBiotricityN/A$0.50+1.8%N/A+10.4%$12.46M$12.06M-0.4640 Related Companies and Tools Related Companies Labcorp Competitors Quest Diagnostics Competitors DaVita Competitors Chemed Competitors CorVel Competitors Amedisys Competitors Pediatrix Medical Group Competitors AMN Healthcare Services Competitors Cross Country Healthcare Competitors Biotricity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDXG) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access